Metagenomi Therapeutics (MGX) Current Deferred Revenue (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Current Deferred Revenue of $9.3 million for Q1 2026, down 63.51% year-over-year from $25.5 million in Q1 2025, and up 6.97% quarter-over-quarter from $8.7 million in Q4 2025.
Metagenomi Therapeutics (MGX) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Current Deferred Revenue for 4 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 63.51% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 63.51% YoY), while the FY2025 annual figure was $8.7 million, down 61.78% from the prior year.
- Current Deferred Revenue climbed to $9.3 million in Q1 2026 per MGX's latest filing, from $8.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $48.3 million in Q1 2024 and bottomed at $8.7 million in Q4 2025.
- Historically, Current Deferred Revenue has averaged $25.7 million across 4 years, with a median of $24.1 million in 2024.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue plunged 42.56% — and 2026, when it plunged 63.51%.
- Metagenomi Therapeutics' Current Deferred Revenue stood at $48.1 million in 2023, then slumped by 52.65% to $22.8 million in 2024, then slumped by 61.78% to $8.7 million in 2025, then rose by 6.97% to $9.3 million in 2026.
- Business Quant data shows MGX's Current Deferred Revenue at $9.3 million in Q1 2026, $8.7 million in Q4 2025, and $12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.20 Mn |
| Mar 31, 2026 | 9.31 Mn |
| Dec 31, 2025 | 8.70 Mn |
| Sep 30, 2025 | 12.90 Mn |
| Jun 30, 2025 | 18.94 Mn |
| Mar 31, 2025 | 25.50 Mn |
| Dec 31, 2024 | 22.76 Mn |
| Sep 30, 2024 | 29.05 Mn |
| Jun 30, 2024 | 32.98 Mn |
| Mar 31, 2024 | 48.29 Mn |
| Dec 31, 2023 | 48.07 Mn |